TargetMol

Cetuximab

Product Code:
 
TAR-T9905
Product Group:
 
Primary Antibodies
Supplier:
 
TargetMol
Antibody Clonality:
 
Monoclonal
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T9905-1mg1mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9905-2mg2mg£303.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9905-5mg5mg£458.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9905-10mg10mg£630.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9905-25mg25mg£962.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Cetuximab (anti-EGFR) a novel molecular-targeted agentis an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation.
CAS:
205923-56-4
Formula:
C107H179N35O36S7
Molecular Weight:
152kd
Pathway:
JAK/STAT signaling; Tyrosine Kinase/Adaptors; Angiogenesis
Purity:
0.98
SMILES:
0
Target:
EGFR

References

H, Gustafsso, A, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model[J]. Cell Biochemistry & Biophysics, 2017. Komatsu M, Nakamura K, Takeda T, et al. Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling. Oncogene. 2022: 1-14. Huang S M , Bock J M , Harari P M . Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation, Apoptosis, and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck1[J]. Cancer Res, 1999, 59(8):1935-1940.